RayzeBio (RYZB) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free RYZB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10, 2024 | nasdaq.comGetting In on This "Macro-Trend"March 3, 2024 | marketbeat.comAcuta Capital Partners LLC Makes New Investment in RayzeBio, Inc. (NASDAQ:RYZB)Acuta Capital Partners LLC acquired a new position in shares of RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 344,571 shares of the company's stockMarch 1, 2024 | marketbeat.comvenBio Partners LLC Makes New $114.51 Million Investment in RayzeBio, Inc. (NASDAQ:RYZB)venBio Partners LLC acquired a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 5,158,162 shares of the company's stock, valued at approximately $114,511,February 29, 2024 | finance.yahoo.comAndreas Halvorsen's Firm Sells Out of RayzeBio IncFebruary 27, 2024 | finance.yahoo.comRYZB Aug 2024 35.000 putFebruary 27, 2024 | finance.yahoo.comRYZB May 2024 55.000 putFebruary 26, 2024 | businesswire.comBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical PlatformFebruary 26, 2024 | marketbeat.comTrading was temporarily halted for "RYZB" at 07:02 PM with a stated reason of "News pending."February 25, 2024 | ca.finance.yahoo.comBMY Mar 2024 54.000 putFebruary 25, 2024 | marketbeat.comMonashee Investment Management LLC Acquires Shares of 27,500 RayzeBio, Inc. (NASDAQ:RYZB)Monashee Investment Management LLC bought a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 27,500 shares of the company's stock, valued at approximately $610,000. OtFebruary 24, 2024 | finance.yahoo.comBMY Apr 2024 43.000 putFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 48.000 callFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 47.000 putFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 43.000 putFebruary 23, 2024 | marketwatch.comBristol Myers Wraps RayzeBio Tender Offer with 86% of SharesFebruary 23, 2024 | businesswire.comBristol Myers Squibb Announces Expiration of RayzeBio Tender OfferFebruary 22, 2024 | benzinga.comRayzeBio Stock (NASDAQ:RYZB), Quotes and News SummaryFebruary 18, 2024 | finance.yahoo.comRYZB Feb 2024 65.000 callFebruary 15, 2024 | marketbeat.comMaven Securities LTD Makes New Investment in RayzeBio, Inc. (NASDAQ:RYZB)Maven Securities LTD bought a new position in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 59,835 shares of the company's stock, valued at approximately $1,328,000. MavenFebruary 14, 2024 | marketbeat.comRayzeBio (NASDAQ:RYZB) Reaches New 12-Month High at $62.42RayzeBio (NASDAQ:RYZB) Reaches New 12-Month High at $62.42February 13, 2024 | finance.yahoo.comBMY Feb 2024 37.000 putFebruary 12, 2024 | finance.yahoo.comBristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting PeriodFebruary 6, 2024 | marketbeat.comVivo Capital LLC Acquires Shares of 633,576 RayzeBio, Inc. (NASDAQ:RYZB)Vivo Capital LLC purchased a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 633,576 shares of the company's stock, valued at approximately $1January 22, 2024 | marketbeat.comVersant Venture Management LLC Acquires New Stake in RayzeBio, Inc. (NASDAQ:RYZB)Versant Venture Management LLC purchased a new position in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,158,161 shares of the company's stock, valued at aJanuary 21, 2024 | marketbeat.comPlatinum Investment Management Ltd. Buys New Position in RayzeBio, Inc. (NASDAQ:RYZB)Platinum Investment Management Ltd. bought a new stake in shares of RayzeBio, Inc. (NASDAQ:RYZB - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 222,222 shares of the company's stock, valued at aJanuary 8, 2024 | marketbeat.comIPO watch 2024: Which new stocks will hit the market? (RYZB)Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies.December 31, 2023 | businesswire.comRAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZBDecember 31, 2023 | businesswire.comRAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZBDecember 29, 2023 | marketbeat.comBristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals (RYZB)Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.December 29, 2023 | marketbeat.comRayzeBio, Inc. (NASDAQ:RYZB) to Post FY2023 Earnings of ($3.25) Per Share, William Blair ForecastsRayzeBio, Inc. (NASDAQ:RYZB - Free Report) - Investment analysts at William Blair increased their FY2023 EPS estimates for shares of RayzeBio in a research note issued on Tuesday, December 26th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($3.25) per share foDecember 28, 2023 | realmoney.thestreet.comRayzeBio just downgraded at JPMorgan, here's whyDecember 28, 2023 | msn.comRBC says Bristol Myers/RayzeBio deal validates Fusion 's approachDecember 28, 2023 | realmoney.thestreet.comRayzeBio downgraded to Hold from Buy at TruistDecember 26, 2023 | finance.yahoo.comBristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%December 26, 2023 | msn.comWhy RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionDecember 26, 2023 | finance.yahoo.comBristol Myers buying RayzeBio, FedEx buyback: Trending tickersDecember 26, 2023 | za.investing.comMidday movers: Intel, RayzeBio, and moreDecember 26, 2023 | benzinga.comHealth Care Company Bristol-Myers Squibb Announces Merger With RayzeBioDecember 26, 2023 | tmcnet.comRYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.December 26, 2023 | seekingalpha.comRayzeBio: New IPO With Good Data And Solid PremiseDecember 26, 2023 | msn.comBristol-Myers Agrees Deal to Buy RayzeBio for About $4.1 BillionDecember 26, 2023 | finance.yahoo.comBristol Myers,RayzeBio deal, AstraZeneca buying GracellDecember 26, 2023 | investorplace.comWhy Is RayzeBio (RYZB) Stock Up 100% Today?December 26, 2023 | marketbeat.comRayzeBio's (RYZB) Market Perform Rating Reaffirmed at William BlairWilliam Blair reiterated a "market perform" rating on shares of RayzeBio in a research report on Tuesday.December 26, 2023 | finance.yahoo.comBristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioDecember 26, 2023 | marketbeat.comTrading was temporarily halted for "RYZB" at 06:12 AM with a stated reason of "News pending."December 12, 2023 | seekingalpha.comTracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2023 UpdateDecember 3, 2023 | benzinga.comRayzeBio Stock (NASDAQ:RYZB) Dividends: History, Yield and DatesNovember 30, 2023 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on RayzeBio, Inc. (RYZB)November 30, 2023 | morningstar.comRayzeBio inc RYZB Get RayzeBio News Delivered to You Automatically Sign up to receive the latest news and ratings for RYZB and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th! Click here now to see his shocking evidence. RYZB Media Mentions By Week RYZB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYZB News Sentiment▼0.000.57▲Average Medical News Sentiment RYZB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYZB Articles This Week▼11▲RYZB Articles Average Week Get RayzeBio News Delivered to You Automatically Sign up to receive the latest news and ratings for RYZB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PACS Group News Iovance Biotherapeutics News Integer News Biohaven News HUTCHMED News Crinetics Pharmaceuticals News Insmed News RadNet News Axsome Therapeutics News Prestige Consumer Healthcare News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYZB) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RayzeBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
